Josamycin

CHF 48.00
In stock
CDX-J0001-M05050 mgCHF 48.00
CDX-J0001-M200200 mgCHF 148.00
CDX-J0001-GG252.5 gCHF 917.00
More Information
Product Details
Synonyms Kitasamycin A3; Leucomycin A3; Turimycin A5
Product Type Chemical
Properties
Formula

C42H69NO15

MW 827.99
CAS 16846-24-5
RTECS OH4725810
Source/Host Chemicals Isolated from Streptomyces narbonensis var. josamyceticus var. nova.
Purity Chemicals ≥98% (UV)
Appearance White to off-white powder.
Solubility Soluble in ethanol (25mg/ml), DMSO (15mg/ml) or DMF (25mg/ml). Sparingly soluble in water (0.05mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key XJSFLOJWULLJQS-LAEWXYAOSA-N
Smiles CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)CC(CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)C([C@H]1O)N(C)C)OC(C)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Josamycin is a member of the leucomycin family of macrolide antibiotics produced by Streptomyces kitasatoensis. It is an antimicrobial against a wide variety of pathogens. It has activity against Gram-positive an Gram-negative bacteria.  The mechanism of action is via inhibition of bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, inhibiting peptidyltransferase and ribosomal translocation, thereby inhibiting translocation of peptidyl tRNA. Josamycin may overcome anticancer drug resistance by inhibiting the binding of vinblastine or cyclosporin A to P-glycoprotein (Pgp). It is used to study the modification of phagocytosis and cytokine production by macrolide antibiotics and immunomodulatory effects.

Product References

(1) K. Nitta, et al.; J. Antibiot. 20, 181 (1967) | (2) T. Osono, et al.; J. Antibiot. 20, 174 (1967) | (3) T. Bergan & B. Oydvin; Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 80, 101 (1972) | (4) E.L. Westerman, et al.; Antimicrob. Agents Chemother. 9, 988 (1976) | (5) R.E. Reese, et al.; Antimicrob. Agents Chemother. 10, 253 (1976) | (6) J.P. Guggenbichler, et al.; Infection 21, 259 (1993) | (7) K. Morikawa, et al.; Antimicrob. Agents Chemother. 38, 2643 (1994) | (8) T. Ono, et al.; Chemotherapy 42, 159 (1996) | (9) L. Wang, et al.; Clin. Exp. Pharmacol. Physiol. 27, 587 (2000) | (10) M. Lovmar, et al.; J. Biol. Chem. 279, 53506 (2004) | (11) E.Y. Choi, et al.; Biomed. Pharmacother. 105, 498 (2018)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.